Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jan 7, 2008; 14(1): 1-14
Published online Jan 7, 2008. doi: 10.3748/wjg.14.1
Table 4 Agents of multi-kinase- and growth factor independent inhibition for the therapy of solid tumours
NameTargetMechanismCurrent status
Sorafenibc-Raf-1,Tyrosine kinase inhibitorApproved for advanced RCC
B-Raf, VEGFR, PDGFRPhase III for advanced HCC[108]
Phase II for melanoma[106], breast cancer[158] and NSCLC[159]
Phase Ifor advanced solid tumours[160]
Everolimus (RAD001)mTORTyrosine kinase inhibitorPhase II for colorectal cancer[165]
PhaseI/II for advanced HCC[117116]
PhaseIfor endometrial and brain tumours[111112]
Temsirolimus (CCI-779)mTORTyrosine kinase inhibitorPhase II for metastatic breast cancer[161], advanced RCC[162], and mantle cell lymphoma[163]
PhaseIfor advanced solid tumours (e.g. colorectal, ovarian, lung cancer)[164]
AP23573mTORTyrosine kinase inhibitorPhase II for sarcomas of soft tissue and bone[114]
PhaseIfor advanced solid tumours
Bortezomib (Velcade)ProetasomeProteasome inhibitorApproved for multiple myeloma and mantle cell lymphoma[125]
Phase II for colorectal cancer[166], neuroendocrine tumours[128], sarcoma[126], RCC[127], and NSCLC[129]
PhaseI/II for unresectable HCC[132]
PhaseIfor advanced solid tumours[167]